Repurposing as a means to increase the activity of amphotericin B and caspofungin against Candida albicans biofilms

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 4, 2014, Pages 1035-1044

  Delattin, Nicolas ^a   De brucker, Katrijn ^a   Vandamme, Katleen ^b   Meert, Els ^a   Marchand, Arnaud ^c   Chaltin, Patrick ^a,c   Cammue, Bruno P A ^a   Thevissen, Karin ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c CISTIM Leuven vzw Bio Incubator 2 Wetenschapspark Arenberg   (Belgium)

Author keywords

Antifungal agents; Drug synergy; Toremifene citrate; Yeast

Indexed keywords

ACAMPROSATE; AMPHOTERICIN B; ANTIFUNGAL AGENT; CASPOFUNGIN; CHLORPROTHIXENE; CLORGYLINE; DANTRON; DICYCLOVERINE; DROSPIRENONE; PERHEXILINE MALEATE; PROCHLORPERAZINE EDISYLATE; TOREMIFENE;

ANTIFUNGAL ACTIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BIOFILM; CANDIDA ALBICANS; CANDIDA GLABRATA; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG POTENTIATION; ENHANCER REGION; FUNGUS GROWTH; HELMINTHIASIS; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TEMPERATURE; NONHUMAN; OSTEOBLAST; PATENT; STAPHYLOCOCCUS EPIDERMIDIS;

ANTIFUNGAL AGENTS; DRUG SYNERGY; TOREMIFENE CITRATE; YEAST;

AMPHOTERICIN B; ANDROSTENES; ANIMALS; ANTIFUNGAL AGENTS; BIOFILMS; CAENORHABDITIS ELEGANS; CANDIDA ALBICANS; DRUG REPOSITIONING; DRUG SYNERGISM; ECHINOCANDINS; MICROBIAL SENSITIVITY TESTS; OSTEOBLASTS; PERHEXILINE; TOREMIFENE;

EID: 84896467050     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt449     Document Type: Article

References (55)

1. Wisplinghoff H, Bischoff T, Tallent SM et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39: 309-17.
2. Gudlaugsson O, Gillespie S, Lee K et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003; 37: 1172-7.
3. Pfaller MA, Diekema DJ. Epidemiology of invasive mycoses in North America. Crit Rev Microbiol 2010; 36: 1-53.
4. Rex JH, Pfaller MA, Barry AL et al. Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. NIAID Mycoses Study Group and the Candidemia Study Group. Antimicrob Agents Chemother 1995; 39: 40-4.
5. Pfaller MA. Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. Am J Med 2012; 125: S3-13.
6. Kojic EM, Darouiche RO. Candida infections of medical devices. Clin Microbiol Rev 2004; 17: 255-67.
7. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science 1999; 284: 1318-22.
8. Kuhn DM, George T, Chandra J et al. Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob Agents Chemother 2002; 46: 1773-80.
9. Spitzer M, Griffiths E, Blakely KM et al. Cross-species discovery of syncretic drug combinations that potentiate the antifungal fluconazole. Mol Syst Biol 2011; 7: 499.
10. Butts A, Krysan DJ. Antifungal drug discovery: something old and something new. PLoS Pathog 2012; 8: e1002870.
11. Wiseman H, Cannon M, Arnstein HR. Observation and significance of growth inhibition of Saccharomyces cerevisiae (A224A) by the anti-oestrogen drug tamoxifen. Biochem Soc Trans 1989; 17: 1038-9.
12. Wiseman H, Cannon M, Arnstein HRet al. Enhancement by tamoxifen of themembrane antioxidant action of the yeastmembrane sterol ergosterol: relevance to the antiyeast and anticancer action of tamoxifen. Biochim Biophys Acta 1993; 1181: 201-6.
13. Beggs WH. Anti-Candida activity of the anti-cancer drug tamoxifen. Res Commun Chem Pathol Pharmacol 1993; 80: 125-8.
14. Beggs WH. Comparative activities of miconazole and the anticancer drug tamoxifen against Candida albicans. J Antimicrob Chemother 1994; 34: 186-7.
15. Parsons AB, Lopez A, Givoni IE et al. Exploring the mode-of-action of bioactive compounds by chemical-genetic profiling in yeast. Cell 2006; 126: 611-25.
16. Dolan K, Montgomery S, Buchheit B et al. Antifungal activity of tamoxifen: in vitro and in vivo activities and mechanistic characterization. Antimicrob Agents Chemother 2009; 53: 3337-46.
17. Butts A, DiDone L, Koselny K et al. A repurposing approach identifies off-patent drugs with fungicidal cryptococcal activity, a common structural chemotype, and pharmacological properties relevant to the treatment of cryptococcosis. Eukaryot Cell 2013; 12: 278-87.
18. Frohner IE, Bourgeois C, Yatsyk K et al. Candida albicans cell surface superoxide dismutases degrade host-derived reactive oxygen species to escape innate immune surveillance. Mol Microbiol 2009; 71: 240-52.
19. Fonzi WA, Irwin MY. Isogenic strain construction and gene mapping in Candida albicans. Genetics 1993; 134: 717-28.
20. Kaur R,MaB, Cormack BP. A familyof glycosylphosphatidylinositol-linked aspartyl proteases is requiredfor virulenceofCandidaglabrata. ProcNatlAcad Sci USA 2007; 104: 7628-33.
21. O'Brien J, Wilson I, Orton T et al. Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. Eur J Biochem 2000; 267: 5421-6.
22. Odds FC. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother 2003; 52: 1.
23. Tellier R, Krajden M, Grigoriew GA et al. Innovative endpoint determination system for antifungal susceptibility testing of yeasts. Antimicrob Agents Chemother 1992; 36: 1619-25.
24. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts-Third Edition: Approved Standard M27-A3. CLSI,Wayne, PA, USA, 2008.
25. Bink A, Kucharikova S, Neirinck B et al. The nonsteroidal antiinflammatory drug diclofenac potentiates the in vivo activity of caspofungin against Candida albicans biofilms. J Infect Dis 2012; 206: 1790-7.
26. Breger J, Fuchs BB, Aperis G et al. Antifungal chemical compounds identified using a C. elegans pathogenicity assay. PLoS Pathog 2007; 3: e18.
27. Thevissen K, Pellens K, De Brucker K et al. Novel fungicidal benzylsulfanylphenylguanidines. Bioorg Med ChemLett 2011; 21: 3686-92.
28. Harriott MM, Noverr MC. Importance of Candida-bacterial polymicrobial biofilms in disease. Trends Microbiol 2011; 19: 557-63.
29. Wargo MJ, Hogan DA. Fungal-bacterial interactions: a mixed bag of mingling microbes. Curr Opin Microbiol 2006; 9: 359-64.
30. Peters BM, Jabra-Rizk MA, O'May GA et al. Polymicrobial interactions: impact on pathogenesis and human disease. Clin Microbiol Rev 2012; 25: 193-213.
31. Peters BM, Ovchinnikova ES, Krom BP et al. Staphylococcus aureus adherence to Candida albicans hyphae is mediated by the hyphal adhesin Als3p. Microbiology 2012; 158: 2975-86.
32. Harriott MM, Noverr MC. Candida albicans and Staphylococcus aureus form polymicrobial biofilms: effects on antimicrobial resistance. Antimicrob Agents Chemother 2009; 53: 3914-22.
33. Harriott MM, Noverr MC. Ability of Candida albicans mutants to induce Staphylococcus aureus vancomycin resistance during polymicrobial biofilm formation. Antimicrob Agents Chemother 2010; 54: 3746-55.
34. Begun J,Gaiani JM, Rohde H et al. Staphylococcalbiofilmexopolysaccharide protects against Caenorhabditis elegans immunedefenses. PLoS Pathog 2007; 3: e57.
35. Darby C, Hsu JW, Ghori N et al. Caenorhabditis elegans: plague bacteria biofilm blocks food intake. Nature 2002; 417: 243-4.
36. Joshua GW, Karlyshev AV, Smith MP et al. A Caenorhabditis elegans model of Yersinia infection: biofilm formation on a biotic surface. Microbiology 2003; 149: 3221-9.
37. Tan L, Darby C. Amovable surface: formation of Yersinia sp. biofilms on motile Caenorhabditis elegans. J Bacteriol 2004; 186: 5087-92.
38. Edwards S, Kjellerup BV. Exploring the applications of invertebrate host-pathogen models for in vivo biofilm infections. FEMS Immunol Med Microbiol 2012; 65: 205-14.
39. Fanning S, Mitchell AP. Fungal biofilms. PLoS Pathog 2012; 8: e1002585.
40. Adam B, Baillie GS, Douglas LJ. Mixed species biofilms of Candida albicans and Staphylococcus epidermidis. J Med Microbiol 2002; 51: 344-9.
41. LaFleur MD, Lucumi E, Napper AD et al. Novel high-throughput screen against Candida albicans identifies antifungal potentiators and agents effective against biofilms. J Antimicrob Chemother 2011; 66: 820-6.
42. Shinde RB, Chauhan NM, Raut JS et al. Sensitization of Candida albicans biofilms to various antifungal drugs by cyclosporine A. Ann Clin Microbiol Antimicrob 2012; 11: 27.
43. Zeidler U, Bougnoux ME, Lupan A et al. Synergy of the antibiotic colistin with echinocandin antifungals in Candida species. J Antimicrob Chemother 2013; 68: 1285-96.
44. Oelkers W, Foidart JM, Dombrovicz N et al. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab 1995; 80: 1816-21.
45. Fenton C, Wellington K, Moen MD et al. Drospirenone/ethinylestradiol 3 mg/20microg (24/4 day regimen): a review of its use in contraception, premenstrual dysphoric disorder and moderate acne vulgaris. Drugs 2007; 67: 1749-65.
46. Cole PL, Beamer AD, McGowan N et al. Efficacy and safety of perhexiline maleate in refractoryangina.Adouble-blindplacebo-controlled clinical trial of a novel antianginal agent. Circulation 1990; 81: 1260-70.
47. Kallio S, Kangas L, Blanco G et al. A new triphenylethylene compound, Fc-1157a. I. Hormonal effects. Cancer Chemother Pharmacol 1986; 17: 103-8.
48. Ariazi EA, Ariazi JL, Cordera F et al. Estrogen receptors as therapeutic targets in breast cancer. Curr Top Med Chem 2006; 6: 181-202.
49. Price D, Stein B, Sieber P et al. Toremifene for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia: results of a double-blind, placebo controlled, phase IIB clinical trial. J Urol 2006; 176: 965-70; discussion 70-1.
50. Taneja SS, Smith MR, Dalton JTet al. Toremifene-a promising therapy for the prevention of prostate cancer and complications of androgen deprivation therapy. Expert Opin Investig Drugs 2006; 15: 293-305.
51. Goldstein SR, Siddhanti S, Ciaccia AV et al. A pharmacological review of selective oestrogen receptor modulators. Hum Reprod Update 2000; 6: 212-24.
52. Hirsimaki P, Aaltonen A, Mantyla E. Toxicity of antiestrogens. Breast J 2002; 8: 92-6.
53. Bozic KJ, Kurtz SM, Lau E et al. The epidemiology of revision total knee arthroplasty in the United States. Clin Orthop Relat Res 2010; 468: 45-51.
54. Kurtz S, Ong K, Lau E et al. Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. J Bone Joint Surg Am 2007; 89: 780-5.
55. Teughels W, Van Assche N, Sliepen I et al. Effect of material characteristics and/or surface topography on biofilm development. Clin Oral Implants Res 2006; 17 Suppl 2: 68-81.